Deutsche Bank Reiterates Buy, $57 PT on Gilead Sciences - Gilead Sciences (NASDAQ:GILD)

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

Deutsche Bank remains Buy-rated with a $57 target price on Gilead Sciences (NASDAQ: GILD) following IMS Week-7 scripts analysis, which suggests higher price realization on the company's HIV franchise.Deutsche Bank says, "GILD took price increases for its HIV franchise on Jan 1st 2012. Price increases in 1Q'12 were Atripla 6.5%, Truvada 7.9%, Viread 4.9% and Complera 7.3%. These increases are additive to the first quarter. We have adjusted the price increase by drug to reflect the discounts in the channel due to ADAPs and public payers. This results in 73% of the full price passed through on GILD's HIV drugs.TRx increase/decrease + adj. price growth."GILD closed at $45.26 a share on Friday.

Crypto Whales Are Loading Up — Are You?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!